Vegetarians have ‘substantially lower risk’ of five types of cancer - The Guardian
Vegetarians have ‘substantially lower risk’ of five types of cancer The Guardian
Kidney Cancer News
Blood in urine ignored for 2 years, Delhi man develops kidney cancer - The Times of India
Blood in urine ignored for 2 years, Delhi man develops kidney cancer The Times of India
Adjuvant Belzutifan-Pembrolizumab Significantly Boosts DFS in Kidney Cancer - MedPage Today
Adjuvant Belzutifan-Pembrolizumab Significantly Boosts DFS in Kidney Cancer MedPage Today
Eisai points the way to kidney cancer support with Kompass digital hub - Fierce Pharma
Eisai points the way to kidney cancer support with Kompass digital hub Fierce Pharma
Kidney cancer study finds belzutifan plus pembrolizumab post-surgery helps patients at high risk for relapse stay cancer-free longer - EurekAlert!
Kidney cancer study finds belzutifan plus pembrolizumab post-surgery helps patients at high risk for relapse stay cancer-free longer EurekAlert!
Toni Choueiri, MD, on key takeaways from LITESPARK-022 in ccRCC - Urology Times
Toni Choueiri, MD, on key takeaways from LITESPARK-022 in ccRCC Urology Times
Brad Arnold, 3 Doors Down 'Kryptonite' Singer, Dies at 47, Months After Kidney Cancer Diagnosis - People.com
Brad Arnold, 3 Doors Down 'Kryptonite' Singer, Dies at 47, Months After Kidney Cancer Diagnosis People.com
Novel Biomarker Model Promises Refined Risk Assessment in Kidney Cancer - Targeted Oncology
Novel Biomarker Model Promises Refined Risk Assessment in Kidney Cancer Targeted Oncology
A new standard? Merck's Welireg combos deliver 1-2 punch to kidney cancer - Fierce Pharma
A new standard? Merck's Welireg combos deliver 1-2 punch to kidney cancer Fierce Pharma
ASCO-GU 2026 – gauging Welireg’s double win | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
ASCO-GU 2026 – gauging Welireg’s double win | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Adding SBRT to Ipilimumab/Nivolumab Does Not Improve PFS in Advanced RCC - CancerNetwork
Adding SBRT to Ipilimumab/Nivolumab Does Not Improve PFS in Advanced RCC CancerNetwork
Kidney Cancer Risks in Young Adults: Genetic Factors and Early Detection - CUREtoday.com
Kidney Cancer Risks in Young Adults: Genetic Factors and Early Detection CUREtoday.com
Poll Results Shed Light on Top Bladder, Kidney Cancer Abstracts to Watch at the 2026 Genitourinary Cancers Symposium - OncLive
Poll Results Shed Light on Top Bladder, Kidney Cancer Abstracts to Watch at the 2026 Genitourinary Cancers Symposium OncLive
LITESPARK-022 DFS data make case for belzutifan/pembrolizumab as new standard in ccRCC - Urology Times
LITESPARK-022 DFS data make case for belzutifan/pembrolizumab as new standard in ccRCC Urology Times
MUSC: Cancer survivor stays in the game - Post and Courier
MUSC: Cancer survivor stays in the game Post and Courier
Eisai unveils digital platform for kidney cancer patients - pharmaphorum
Eisai unveils digital platform for kidney cancer patients pharmaphorum
More Sensitive Cell Therapy May Be a HIT Against Solid Cancers - Columbia University Irving Medical Center
More Sensitive Cell Therapy May Be a HIT Against Solid Cancers Columbia University Irving Medical Center
Warning Signs of Kidney Cancer You Shouldn’t Ignore - Fox Chase Cancer Center
Warning Signs of Kidney Cancer You Shouldn’t Ignore Fox Chase Cancer Center
Improved PFS in Advanced Kidney Cancer With Antiangiogenic Combination - MedPage Today
Improved PFS in Advanced Kidney Cancer With Antiangiogenic Combination MedPage Today
Casdatifan Exhibits 1+ Year Survival in Later-Line Kidney Cancer - CancerNetwork
Casdatifan Exhibits 1+ Year Survival in Later-Line Kidney Cancer CancerNetwork
Belzutifan/Lenvatinib Bests Cabozantinib in PFS, ORR in ccRCC - Targeted Oncology
Belzutifan/Lenvatinib Bests Cabozantinib in PFS, ORR in ccRCC Targeted Oncology
Data Show Comparable Immunotherapy Outcomes Across RCC Age Populations - CancerNetwork
Data Show Comparable Immunotherapy Outcomes Across RCC Age Populations CancerNetwork
Merck looks to expand Welireg label following combo readouts with Keytruda, Lenvima - Endpoints News
Merck looks to expand Welireg label following combo readouts with Keytruda, Lenvima Endpoints News
Eisai and Advocacy Leaders Launch "Kompass," a Digital Destination to Help Patients and Caregivers Navigate the Complexities of Kidney Cancer - BioSpace
Eisai and Advocacy Leaders Launch "Kompass," a Digital Destination to Help Patients and Caregivers Navigate the Complexities of Kidney Cancer BioSpace
Combination Therapies Deliver Major Gains in Bladder and Kidney Cancer Survival - Mega Doctor News
Combination Therapies Deliver Major Gains in Bladder and Kidney Cancer Survival Mega Doctor News
Vegetarian diets and cancer risk: pooled analysis of 1.8 million women and men in nine prospective studies on three continents | British Journal of Cancer - Nature
Vegetarian diets and cancer risk: pooled analysis of 1.8 million women and men in nine prospective studies on three continents | British Journal of Cancer Nature
Kidney cancer specialists: 3 things to know about renal cell carcinoma (RCC) - MD Anderson Cancer Center
Kidney cancer specialists: 3 things to know about renal cell carcinoma (RCC) MD Anderson Cancer Center
Adjuvant Pembrolizumab Plus Belzutifan Improves DFS in Clear Cell RCC - OncLive
Adjuvant Pembrolizumab Plus Belzutifan Improves DFS in Clear Cell RCC OncLive
Radium‑223 (Xofigo) Plus Enzalutamide (Xtandi) Boosts Survival in Metastatic Prostate Cancer - Oncology News Central
Radium‑223 (Xofigo) Plus Enzalutamide (Xtandi) Boosts Survival in Metastatic Prostate Cancer Oncology News Central
ASCO GU 2026 Preview: Highlights of Key Trials in Bladder, Kidney, Prostate, and Rare Cancers - Targeted Oncology
ASCO GU 2026 Preview: Highlights of Key Trials in Bladder, Kidney, Prostate, and Rare Cancers Targeted Oncology
New Study Shows Belzutifan and Pembrolizumab Combo Extends Cancer-Free - BIOENGINEER.ORG
New Study Shows Belzutifan and Pembrolizumab Combo Extends Cancer-Free BIOENGINEER.ORG
Kidney Cancer Cases Are Projected to Double by 2050, Says Study - Fox Chase Cancer Center
Kidney Cancer Cases Are Projected to Double by 2050, Says Study Fox Chase Cancer Center
Lead singer of 3 Doors Down dies at 47 after kidney cancer battle - Yahoo
Lead singer of 3 Doors Down dies at 47 after kidney cancer battle Yahoo
Ultra-Sensitive CAR T Cells May Unlock Potential Therapeutic Strategy for Solid Tumors - GEN - Genetic Engineering and Biotechnology News
Ultra-Sensitive CAR T Cells May Unlock Potential Therapeutic Strategy for Solid Tumors GEN - Genetic Engineering and Biotechnology News
A clinically validated AI framework for kidney cancer detection and characterization | Communications Medicine - Nature
A clinically validated AI framework for kidney cancer detection and characterization | Communications Medicine Nature
Targeting of HIF2-driven cachexia in kidney cancer - Nature
Targeting of HIF2-driven cachexia in kidney cancer Nature
Renal Cell Carcinoma: Background, Pathophysiology, Etiology - Medscape eMedicine
Renal Cell Carcinoma: Background, Pathophysiology, Etiology Medscape eMedicine
Kidney Cancer Remission Rate: What Patients Need to Know in 2025 - Oncodaily
Kidney Cancer Remission Rate: What Patients Need to Know in 2025 Oncodaily
Kidney Cancer Experts Preview Practice-Shaping Trials Taking Center Stage at ASCO GU 2026 - OncLive
Kidney Cancer Experts Preview Practice-Shaping Trials Taking Center Stage at ASCO GU 2026 OncLive
WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC) - WFXG
WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC) WFXG